Humacyte (HUMA) risk factors

Humacyte faces significant commercialization, manufacturing, and clinical trial risks as it attempts to market its sole approved product, Symvess. The company has incurred substantial accumulated deficits and requires additional capital to fund its ongoing operations and pipeline development. Intellectual property protection and compliance with stringent FDA regulations are critical for business viability.